Want to see HK:2591 full AI Analyst Report?
2591 Stock Chart & Stats
HK$7.10
--
Market closed
HK$7.10
--
Day’s Range― - ―
52-Week RangeHK$3.78 - HK$48.36
Previous CloseN/A
VolumeN/A
Average Volume (3M)470.32K
Market Cap
HK$1.73B
Enterprise ValueHK$2.23K
Total Cash (Recent Filing)HK$1.02B
Total Debt (Recent Filing)HK$151.19M
Price to Earnings (P/E)―
Beta1.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding420,285,370
10 Day Avg. Volume352,882
30 Day Avg. Volume470,322
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)11.34
Price to Sales (P/S)93.25
P/FCF Ratio-37.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.70Price Target Upside135.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue InflectionThe sharp 2025 revenue inflection indicates that commercialization has begun and provides a foundation for future operating leverage. Sustained adoption and further scaling could improve the economics of the business over the next several quarters.
Strong Gross MarginAn approximately 81.5% gross margin suggests the underlying products may have attractive economics once sales scale. If maintained, this margin profile could help revenue growth translate into improved profitability after commercial and development costs moderate.
Meaningful Equity And Moderate LeverageThe sizable equity base and moderate leverage provide some financial flexibility for an R&D-intensive biotech. This funding cushion can support development and commercialization initiatives, reducing immediate balance-sheet pressure while the company works toward scale.
Bears Say
Persistent Operating LossesVery large losses relative to revenue show that the current cost base remains far ahead of commercialization. Without substantial revenue scale-up or expense discipline, the company may remain dependent on external funding and face a prolonged path to profitability.
Ongoing Cash BurnNegative operating and free cash flow across all reported years indicates that the business is not yet self-funding. Continued investment may support growth, but persistent burn can erode liquidity and require additional financing before revenues and margins mature.
Rising Debt And Funding RiskAlthough leverage remains moderate, materially higher debt alongside negative returns signals increasing reliance on financing while losses persist. If cash burn continues, further borrowing or equity issuance could dilute shareholders or constrain strategic flexibility.
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H News
2591 FAQ
What was Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price range in the past 12 months?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H lowest stock price was HK$3.77 and its highest was HK$48.36 in the past 12 months.
What is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s market cap?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s market cap is HK$1.73B.
When is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s earnings last quarter?
Currently, no data Available
Is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H overvalued?
According to Wall Street analysts Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price is currently Undervalued.
Does Guangzhou Innogen Pharmaceutical Group Co Ltd Class H pay dividends?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H does not currently pay dividends.
What is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s EPS estimate?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guangzhou Innogen Pharmaceutical Group Co Ltd Class H have?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H has 420,285,370 shares outstanding.
What happened to Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Guangzhou Innogen Pharmaceutical Group Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$16.70 (135.21% Upside)
HK$16.70 (135.21% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
46.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co Ltd operates as a China-based investment holding firm with a core mission to research, develop, and bring to market medicinal products. The company specializes in producing innovative, human-compatible, and extended-duration GLP-1 receptor agonists, specifically targeting the treatment of diabetes and other metabolic conditions.
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (2591) Earnings & Revenues
2591 Stock 12 Month Forecast
Average Price Target
HK$16.70
▲(135.21% Upside)
Technical Analysis
Alphamab Oncology
―
RemeGen Co. Ltd. Class H
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―